Form 4: Annexon Director Buys 4,115 Shares Under 10b5-1 Plan

Annexon Inc. Director William H. Carson acquired 4,115 shares of common stock at a weighted average price of $4.47 per share through a pre-arranged trading plan.

Summary

• William H. Carson, a Director of Annexon, Inc. (ANNX), acquired 4,115 shares of common stock.
• The transaction occurred on December 1, 2025, at a weighted average purchase price of $4.47 per share, with prices ranging from $4.43 to $4.50.
• The purchase was executed pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2025.
• Following this transaction, Mr. Carson beneficially owns 50,290 shares of Annexon, Inc. common stock.

Sentiment

Score: 7

Explanation: The insider purchase by a director suggests confidence in the company's valuation and future, which is generally a positive signal for investors. The transaction being under a 10b5-1 plan makes it a planned rather than reactive purchase, indicating a deliberate long-term investment strategy.

Positives

• A company director, William H. Carson, increased his stake in Annexon, Inc. by purchasing 4,115 shares.
• The purchase was made at a weighted average price of $4.47 per share, indicating a direct investment in the company's equity.
• The transaction was conducted under a Rule 10b5-1 trading plan, suggesting a pre-planned investment strategy and potentially long-term confidence.

Future Outlook

NA

Industry Context

Insider buying, particularly by a director, can signal confidence in the company's future prospects, which is often viewed positively by the market, especially in the biotechnology sector where long-term development and clinical milestones are key drivers.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign of management's belief in the company's long-term value and prospects.

Key Dates

Recommendation

The director's purchase of shares, even under a 10b5-1 plan, indicates a level of confidence in Annexon's future. While insider buying is generally a positive signal, this single transaction alone may not warrant an immediate 'buy' recommendation without further fundamental analysis of the company's financial health and strategic outlook. It reinforces a 'hold' position for existing investors and suggests potential for further investigation for new investors.

Keywords

Annexon, ANNX, Form 4, Insider Trading, Director Purchase, Stock Acquisition, William H. Carson, 10b5-1 Plan, Biotechnology